Track record · closed signal

Johnson & Johnson (JNJ) — closed signal from March 1, 2026

Partial Published before the outcome was known, scored automatically when the window closed on May 30, 2026.

Predicted vs. what happened

JNJ price · publication thesis → realized outcomesplit-adjusted

$244.00 – $251.00Entry zone — fair-value band

$248.43Published — price the day we called it

$273.27Target — the price the thesis aimed for

$251.71Peak — highest point inside the window, not a realized return

$225.33Window close — end-of-window price, context only

What happened

Partial

Reached 13% of the predicted growth at its peak, without hitting the target.

Peak price

$251.71

peak on March 2, 2026 — not a realized return

Peak gain

+1.3%

peak, from the publication price

Window close

$225.33

end-of-window price, context only

Days to target

—

Window

March 1, 2026 – May 30, 2026

The thesis — published March 1, 2026

Predicted growth

+10%

over the measurement window

Target price

$273.27

the price the thesis aimed for

Entry zone

$244.00 – $251.00

the fair-value band we waited for

Price at publication

$248.43

published March 1, 2026

Confidence

69%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

JNJ is a defensive stock to hold for a few months. Recent media attention about its price can attract extra buyers. The share price is settling after a strong gain, so buying on small drops into the $244-$251 area offers better risk control than chasing higher prices. It's useful for stability if markets wobble, not for a quick big move.

Primary drivers

Positive pricing headlines can attract steady buyer interest
Health businesses often hold value when markets fall
Buying in the $244-$251 area avoids chasing gains
Growth may be gradual without a clear near-term event

How it played out

JNJ: target was not reached

Lyra published JNJ on 2026-03-01 at $248.43 for a short-term window through 2026-05-30. The thesis expected 10% growth toward $273.27. It pointed to positive pricing headlines, defensive healthcare demand, buying in the $244-$251 area, and gradual growth without a clear near-term event.

The stock peaked at $251.71 on 2026-03-02, with a 1.3% gain. That stayed below the $273.27 target. It never got there. By the end of the window, JNJ was at $225.33. The thesis missed on price action, even though the early peak was slightly above the entry area.

What happened during the window

On April 14, 2026, Johnson & Johnson reported first-quarter sales of $24.06 billion and raised its full-year forecast, according to the Wall Street Journal. Investor's Business Daily also reported on April 14, 2026 that the stock wavered after the report and closed at $240.10.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All JNJ signals